These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25420713)

  • 21. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    de Boer PT; Kelso JK; Halder N; Nguyen TP; Moyes J; Cohen C; Barr IG; Postma MJ; Milne GJ
    Vaccine; 2018 Feb; 36(7):997-1007. PubMed ID: 29373192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
    Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study.
    Shasha D; Valinsky L; Hershkowitz Sikron F; Glatman-Freedman A; Mandelboim M; Toledano A; Paran Y; Ben-Ami R; Goldman D
    Clin Microbiol Infect; 2020 Jan; 26(1):101-106. PubMed ID: 31108229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.
    Wang L; Chandrasekaran V; Domachowske JB; Li P; Innis BL; Jain VK
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):170-9. PubMed ID: 26407273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
    Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY; Zhang JY; Zhang ZG; Luo D; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1636-1641. PubMed ID: 30572392
    [No Abstract]   [Full Text] [Related]  

  • 34. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
    Yun JW; Choi MJ; Shin GS; Lim JO; Noh JY; Kim YK; Song JY; Kim WJ; Choi SE; Cheong HJ
    PLoS One; 2019; 14(1):e0209643. PubMed ID: 30682030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
    Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of the health economic consequences of quadrivalent influenza vaccination.
    de Boer PT; van Maanen BM; Damm O; Ultsch B; Dolk FCK; Crépey P; Pitman R; Wilschut JC; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):249-265. PubMed ID: 28613092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
    Milne GJ; Halder N; Kelso JK; Barr IG; Moyes J; Kahn K; Twine R; Cohen C
    Influenza Other Respir Viruses; 2016 Jul; 10(4):324-32. PubMed ID: 26663701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.